GOTHENBURG, Sweden--(BUSINESS WIRE)--Regulatory News: Through the signing of the licensing agreement, Vitrolife (STO:VITR) secures exclusive worldwide rights to develop, manufacture and sell culture media for pluripotent stem cells. The contract was signed with Finn-Medi Research Ltd, the contractual partner of the Regea Institute for Regenerative Medicine, where development has been carried out. Regea is an independent institute at the University of Tampere, Finland.
